These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
145 related items for PubMed ID: 12856804
1. Lumbar bone mineral density in prostate cancer patients with bone metastases. Chang CH, Tsai CS, Jim YF, Wu HC, Lin CC, Kao A. Endocr Res; 2003 May; 29(2):177-82. PubMed ID: 12856804 [Abstract] [Full Text] [Related]
2. Is bone mineral density measurement using dual-energy X-ray absorptiometry affected by gamma rays? Xie LJ, Li JF, Zeng FW, Jiang H, Cheng MH, Chen Y. J Clin Densitom; 2013 May; 16(3):275-278. PubMed ID: 23473956 [Abstract] [Full Text] [Related]
3. Quantification evaluation of 99mTc-MDP concentration in the lumbar spine with SPECT/CT: compare with bone mineral density. Huang K, Feng Y, Liu D, Liang W, Li L. Ann Nucl Med; 2020 Feb; 34(2):136-143. PubMed ID: 31768820 [Abstract] [Full Text] [Related]
4. Correlation between BMD and bone scintigraphy in patients with prostate cancer. Perk H, Yildiz M, Kosar A, Cerci S, Soyupek F, Ozorak A, Dilmen C. Urol Oncol; 2008 Feb; 26(3):250-3. PubMed ID: 18452814 [Abstract] [Full Text] [Related]
5. Antecedent 99mTc-MDP and 99mTc-sestamibi administration corrupts bone mineral density measured by DXA. McKiernan FE, Hocking J, Cournoyer S. J Clin Densitom; 2006 Feb; 9(2):164-6. PubMed ID: 16785076 [Abstract] [Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Feb; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
8. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP. Pietrzak A, Czepczynski R, Wierzchoslawska E, Cholewinski W. Hell J Nucl Med; 2017 Feb; 20(3):237-240. PubMed ID: 29177262 [Abstract] [Full Text] [Related]
9. [Bone mineral density change: comparison between prostate cancer patients with or without metastases and healthy men (a North African ethnic group)]. Janane A, Hajji F, Ismail T, Jawad C, Crepin-Elondo J, Ghadouane M, Ameur A, Abbar M, Albouzidi A. Actas Urol Esp; 2011 Feb; 35(7):414-9. PubMed ID: 21550141 [Abstract] [Full Text] [Related]
13. Study on the distribution features of bone metastases in prostate cancer. Wang C, Shen Y. Nucl Med Commun; 2012 Apr; 33(4):379-83. PubMed ID: 22293499 [Abstract] [Full Text] [Related]
14. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases. Ozcan Kara P, Kara T, Kara Gedik G, Sari O, Sahin O. Rev Esp Med Nucl; 2011 Apr; 30(2):94-6. PubMed ID: 21342722 [Abstract] [Full Text] [Related]
15. Fibular findings in carcinoma prostate; a challenging situation for reporting physician. Rashid N, Javed MM, Hassan A. J Pak Med Assoc; 2019 Oct; 69(10):1572-1573. PubMed ID: 31622322 [Abstract] [Full Text] [Related]
16. Bone mineral density and bone scintigraphy in adult Saudi female patients with osteomalacia. El-Desouki MI, Othman SM, Fouda MA. Saudi Med J; 2004 Mar; 25(3):355-8. PubMed ID: 15048176 [Abstract] [Full Text] [Related]
17. Bone mineral density for patients with bone metastasis of prostate cancer: a preliminary report. Tanaka H, Furukawa Y, Fukunaga K, Fukunaga M. Adv Exp Med Biol; 1992 Mar; 324():217-31. PubMed ID: 1492619 [Abstract] [Full Text] [Related]
19. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (99mTc-HMDP) Bone Scintigraphy for Bone Metastases from Prostate Cancer Using Deep Learning Algorithms. Higashiyama S, Yoshida A, Kawabe J. Curr Med Imaging; 2021 Mar; 17(1):89-96. PubMed ID: 32484112 [Abstract] [Full Text] [Related]